Indole-containing arene-ruthenium complexes with broad spectrum activity against antibiotic-resistant bacteria

Victoria C. Nolan, Laia Rafols, James Harrison, Joan J. Soldevila-Barreda, Marialuisa Crosatti, Natalie J. Garton, Malgorzata Wegrzyn, Danielle L. Timms, Colin C. Seaton, Helen Sendron, Maria Azmanova, Nicolas P.E. Barry, Anaïs Pitto-Barry, Jonathan A.G. Cox

 PII:
 S2666-5174(21)00079-1

 DOI:
 https://doi.org/10.1016/j.crmicr.2021.100099

 Reference:
 CRMICR 100099



To appear in: Current Research in Microbial Sciences

Received date:26 October 2021Revised date:13 December 2021Accepted date:13 December 2021

Please cite this article Victoria C. Nolan. as: Laia Rafols. James Harrison. Joan J. Soldevila-Barreda. Marialuisa Crosatti. Natalie J. Garton . Malgorzata Wegrzyn, Danielle L. Timms, Colin C. Seaton, Helen Sendron, Maria Azmanova, Nicolas P.E. Barry, Anaïs Pitto-Barry, Jonathan A.G. Cox, Indole-containing arene-ruthenium complexes with broad spectrum activity against antibiotic-resistant bacteria, Current Research in Microbial Sciences (2021), doi: https://doi.org/10.1016/j.crmicr.2021.100099

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Indole-containing arene-ruthenium complexes with broad spectrum activity against antibioticresistant bacteria

Victoria C. Nolan^{1‡}, Laia Rafols^{2‡}, James Harrison¹, Joan J. Soldevila-Barreda², Marialuisa Crosatti³, Natalie J. Garton⁴, Malgorzata Wegrzyn³, Danielle L. Timms,¹ Colin C. Seaton,² Helen Sendron², Maria Azmanova², Nicolas P. E. Barry², Anaïs Pitto-Barry^{2,5}*, Jonathan A. G. Cox¹*

¹ College of Health and Life Sciences, Aston University, B4 7ET, Birmingham, United Kingdom

² School of Chemistry and Biosciences, University of Bradford, BD7 1DP, Bradford, United Kingdom

³CL3 facility, Division of Biomedical Services, University of Leicester, LE1 7RH, Leicester, United Kingdom

⁴Department of Respiratory Sciences and Leicester TB Research Group, University of Leicester, LE1 7RH, Leicester, United Kingdom

⁵ Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92296 Châtenay-Malabry, France

[†]These authors contributed equally to this work

* correspondance: anais.pitto-barry@universite-paris-saclay.fr; j.a.g.cox@aston.ac.uk

Highlights

- A new family of indole-containing arene ruthenium organometallic compounds are active against several bacterial species and drug resistant strains
- Bactericidal activity observed against various Gram negative, Gram positive and acid-fast bacteria, demonstrating broad-spectrum inhibitory activity
- Compound series exhibits low toxicity against human cells
- Shows considerable promise as next generation antibiotics

Abstract

Antimicrobial resistant (AMR) bacteria are emerging and spreading globally, threatening our ability to treat common infectious diseases. The development of new classes of antibiotics able to kill or inhibit the growth of such AMR bacteria through novel mechanisms of action is therefore urgently needed. Here, a new family of indole-containing arene ruthenium organometallic compounds are screened against several bacterial species and drug resistant strains. The most active complex [(*p*-cym)Ru(O-cyclohexyl-1*H*-indole-2-carbothioate)Cl] (**3**) shows growth inhibition and bactericidal activity against different organisms (*Acinetobacter baumannii, Mycobacterium abscessus, Mycobacterium tuberculosis, Staphylococcus aureus, Salmonella enterica serovar typhi* and *Escherichia coli*), demonstrating broad-spectrum inhibitory activity. Importantly, this compound series exhibits low toxicity against human cells. Owing to the novelty of the antibiotic family, their moderate cytotoxicity, and their inhibitory activity against Gram positive, Gram negative and acid-fast, antibiotic resistant microorganisms, this series shows significant promise for further development.

Introduction


Antibiotic resistance is a worldwide threat to public health, food security, and economic and societal developments.¹ The prevalence of antimicrobial resistance (AMR) among common pathogens is rapidly increasing, which leads to widespread diseases becoming harder, or impossible, to cure. AMR organisms of interest include *Acinetobacter baumannii, Escherichia coli, Salmonella sp.* and several other multidrug-resistant Gram-negative organisms.² In the last decades, a global effort has allowed the development of new antibiotic drugs with activity against common AMR organisms,³ but resistance against such agents is already emerging. There is therefore an urgent need to find new families of compounds with high levels of antibacterial activity, novel mechanisms of action and low frequencies of antibiotic resistance.

Inorganic metallodrugs offer potential for unique mechanisms of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated ligands and the coordination geometry.^{4, 5} As such, medicinal inorganic chemistry provides a rich platform in the pharmacological space for structural and electronic diversity.⁶ Medicinal inorganic chemistry has been stimulated by the success of platinum anticancer drugs (used as a component of nearly 50% of all cancer chemotherapy treatments), by the use of gadolinium(III) complexes as MRI contrast agents (about 20 million doses administered per year), and of the radionuclide 99m-technetium radiopharmaceuticals for γ-ray imaging (used in about 20 million radio diagnostic procedures each year).⁷⁻¹⁰ However, the involvement of metals in many other diseases and conditions is of current interest in relation to their causes, their treatment or detection, including neurodegeneration,¹¹

fungal¹², parasitic,^{13, 14} viral¹⁵ infections and inflammation.¹⁶ In the last decades, a wide range of inorganic and organometallic compounds have been investigated for killing or inhibiting microbial growth.¹⁷⁻³³

The antimicrobial activity of some half-sandwich "piano-stool" complexes of precious metals (Ru, Os, Rh, Ir) has very recently proven to be highly promising in our current fight against AMR, with demonstrated potency against drug-resistant strains of *Mycobacterium tuberculosis*.³⁴ Half-sandwich complexes are versatile and highly modifiable organometallics, which contains a π -bonded neutral arene or negatively charged cyclopentadienyl ligand, and, usually, one monodentate and one bidentate ligand. The monodentate and bidentate ligands allow further structural and electronic control of reactivity, including the incorporation of bio-active moieties.

We have recently developed an interest in investigating the effect of bio-active indole moieties as bidentate ligands on the biological properties of half-sandwich metal complexes.³⁵ Indoles are bicyclic heterocycles that are commonly found in plants, bacteria and animals. Natural and synthetic indole-based compounds have widely been used as antibacterial, antifungal, anti-inflammatory, antihistaminic and anticancer drugs.^{36, 37} Examples of such compounds currently in clinical use are the non-steroidal anti-inflammatory drug indomethacin³⁸ or the antiretroviral delavirdine.³⁹



Scheme 1. Preparation of the indole-based ligands L6 – L9 and complexes 1 – 4.

Herein, we report the synthesis and characterisation of a new family of four ruthenium halfsandwich complexes containing O-R-1*H*-indole-2-carbothioate (O-R-ind-th; R = methyl, ethyl, cyclohexyl, phenyl) [(*p*-cym)Ru(O-Me-ind-th)Cl] (1), [(*p*-cym)Ru(O-Et-ind-th)Cl] (2), [(*p*-cym)Ru(O-Cyind-th)Cl] (3), [(*p*-cym)Ru(O-Ph-ind-th)Cl] (4) (Scheme 1). Their stability in solution, hydrolysis rates and acid dissociation constants are studied, along with toxicity data on three human cell lines for both ligands and complexes. The bactericidal activity of the four ligands and complexes against several drug resistant isolates of *Escherichia coli* (*E. coli J53 2138*, a clinical isolate producing the extended spectrum β -lactamase (ESBL) OXA-1, which confers resistance to ampicillin, ticarcillin, piperacillin and cephalosporins, *E. coli J53 2140E*, producing the ESBL OXA-3) is reported.

Results and discussions

Synthesis, stability in solution, aquation and pKa determination

The indole 2-carboxylate ligands L2 - L5 were synthesised by esterification of 1H-indole-2-carboxylic acid (L1) with the corresponding alcohol (MeOH, EtOH, CyOH, PhOH, respectively). Thiolation of the carboxylic group of ligands L2 – L5 was performed by refluxing the corresponding ligands with the Lawesson's reagent in toluene to yield the O-R-1H-indole-2-carbothioate ligands L6 – L9 (R = methyl, ethyl, cyclohexane, benzene; Scheme 1; Experimental Section). Complexes 1 - 4 were then prepared by stirring the dichloro(p-cym)ruthenium(II) dimer with the corresponding ligand (L6 – L9) in dry dichloromethane at ambient temperature and in the presence of triethylamine. All ligands and complexes were characterised by ¹H and ¹³C NMR spectroscopy, and high-resolution ESI-MS (Experimental Section). ¹H and ¹³C NMR spectra can be found in the Supporting Information (Figures S1 – S24), as well as the HR mass spectra (Figures S25 – S36). As an example, Figure 1 shows the 1 H NMR spectra of L4 (bottom), L8 (middle), and complex 3 (top) in $CDCl_3$. The lowest field region (9.5 – 7.0 ppm) shows the aromatic protons of the indole based substituent, followed by the region of the coordinated arene (5.5 - 4.0 ppm), and by the aliphatic region (4.0 - 0.5 ppm). Chemical shifts for the protons located near the ligand heteroatoms that bind to the metal can be observed, for example, the proton of the CH cyclohexyl bonded to the oxygen/sulfur (Figure 1) can be seen to shift upfield from the free ligand L8 to the metal complex 3. Such shifts can be explained by the stereoelectronic effects due to the coordination to the metal moiety, as previously observed.³⁵ The signal for the NH proton is also no more visible after complexation, which confirms the successful synthesis of the complex.




Figure 1. ¹H NMR spectra of **L4** (bottom), **L8** (middle), and complex **3** (top) in CDCl₃ (400 MHz). Residual solvents are marked with a cross.

Crystals of ligand **L5** and complexes 2 [(*p*-cym)Ru(O-Et-ind-th)Cl], **3** [(*p*-cym)Ru(O-Cy-ind-th)Cl], and **4** ([(*p*-cym)Ru(O-Ph-ind-th)Cl], suitable for X-ray structure determination, were obtained by slow diffusion of hexane into a saturated dichloromethane solution at 20 °C. The crystallographic data and selected bond lengths and angles are given in Tables S1 – S12, and the crystal structures are shown in Figure 2 and Figure S40. Complexes **2-4** adopt a pseudo-octahedral structure with Ru^{II} bound to a η^6 -*para*-cymene ring, a *N*,*S*-chelated indole and chloride as ligands to form an 18-electron complex with "piano-stool" geometry.




Figure 2. Structures of ligand L5 (left) and Ru^{II} complex 4 (right). Thermal ellipsoids are drawn at the 50% probability level.

To investigate the stability of complexes 1 - 4, the compounds were dissolved in a mixture (1:1) (v/v) of DMSO/RPMI and UV-Vis spectra were recorded over 24 h (Figure 3). The absorption band at 420 nm gradually decreases while the one at 350 nm concomitantly increases, intersecting at the isosbestic point, which indicates that only the chloride and the hydrolysed forms of the complex contribute to the observed absorptions.⁴⁰⁻⁴³ The time dependence of the absorbance allows for the determination of the rate constants by plotting the absorbance *versus* time at fixed wavelength for each compound (Table 1). The hydrolysis rate depends on the ester group of the indole ligand. Complex **4** (the only complex containing an aromatic R substituent) presents the fastest hydrolysis. The rate of hydrolysis of complexes 1 - 3, with aliphatic R groups, suggests that the bulkier the R substituent is, the slower the aquation process is.




Figure 3. UV–vis spectra of complex **2** in the mixture DMSO/RPMI over time (10⁻⁵ M, 298 K, 24 h).

Aquation of the monodentate ligand X is a common behaviour for half-sandwich complexes of the type [(arene)M(NUS)X] and is usually considered an activation step, which allows further reactions with the corresponding targets.⁴⁴⁻⁴⁷ Solutions ranging from pH 7 to 12 were prepared using 0.1 M NaOH solution, and complexes 1 - 4 (previously dissolved in pure acetonitrile) were added to the corresponding solution with a known pH and mixed for 10 min. Spectra were recorded by UV-visible spectroscopy. The pKa values of the complexes were calculated using Origin 2019 by plotting the absorbance at the corresponding wavelength against the pH and fitting it to the Boltzmann equation to obtain the inflection point. For complexes 1 - 4, the pKa values were calculated to be around 10 (Experimental section and Table 1). These pKa values are high, although such decrease in acidity has been previously reported (generally attributed to an increased electron density on the metal centre).^{44, 48, 49} As a consequence of such high pKa values, only the aqua adduct of the metal complexes is expected to be present at physiological pH (7.4), thus favouring the reaction between the metal complexes with possible ligands such as nucleobases or proteins.

Table 1. Reactivity of complexes 1 - 4. pKa values measured using UV-Vis spectroscopy (10^{-5} M, 298 K), solvent acetonitrile/water v/v. Aquation constants and rates of hydrolysis measured using UV-Vis spectroscopy (10^{-5} M, 298K), in a mixture (1:1) DMSO/RPMI v/v.

Compound	pKa	Kaquation (S ⁻¹)
[(p-cym)Ru(O-Me-ind-th)Cl] (1)	10.34 ± 0.07	$2.0 \text{ x}10^{-4} \pm 6 \text{ x} 10^{-5}$
[(p-cym)Ru(O-Et-ind-th)Cl] (2)	10.24 ± 0.09	$1.8 \text{ x} 10^{-4} \pm 4 \text{ x} 10^{-5}$
[(p-cym)Ru(O-cy-ind-th)Cl] (3)	9.81 ± 0.07	$1.2 \text{ x} 10^{-4} \pm 3 \text{ x} 10^{-5}$
[(p-cym)Ru(O-ph-ind-th)Cl] (4)	10.07 ± 0.05	$2.4 \text{ x} 10^{-4} \pm 4 \text{ x} 10^{-5}$

Toxicity studies against human cells

Toxicity data against human cells is important information for the identification of a novel family of antibiotic drug candidates. Initially developed for anticancer activity, complexes 1 - 4 (and ligands L6 – L9) were tested against human ovarian adenocarcinoma (A2780), cisplatin-resistant variant of A2780 (A2780cisR) and normal human prostate epithelial (PNT2) cell lines. Half-maximal inhibitory concentrations (IC₅₀) were determined using a 24 h MTT assay with 48 h recovery period. The IC₅₀ values are shown in table 2 and the IC₅₀ graphs for ligands L6 – L9 and complexes 1 - 4 against PNT2, A2780, and A2780cisR can be found in the Supporting Information (Figures S37 – S38).

Complexes **1**, **2** and **3** are moderately cytotoxic against the tested cell lines and showed 2 - 3x higher IC₅₀ values towards normal prostate cells in comparison to cancer cells. They are also less toxic than cisplatin against all cell lines. Complex **4** exhibits only low toxicity against the three cell lines.

	IC50 values (µM)		
Compound	A2780	A2780cisR	PNT2
L6	>100	>100	>100
L7	>100	>100	>100
L8	72 ± 2	76 ± 5	71 ± 5
L9	21 ± 1	20 ± 2	26 ± 2
. 1	22 ± 1	28 ± 1	32 ± 2
2	12 ± 2	22 ± 2	37 ± 2
3	10.7 ± 0.6	15.3 ± 0.9	20.8 ± 0.9
4	68 ± 4	83 ± 3	96 ± 6
cisplatin	5.9 ± 0.4	11.8 ± 0.8	26.1 ± 0.6

Table 2. IC₅₀ values (μ M) in A2780, A2780 cisplatin resistant and PNT2 cells for ligands L6 – L9 andfor complexes 1 – 4.

Antibiotic activity

A concentration range of complexes **1** – **4** were tested and activity was observed for a range of organisms, including *Mycobacterium abscessus, Escherichia coli, Staphylococcus aureus, Acinetobacter baumannii, Salmonella enterica* serovar *Typhi* and *Mycobacterium tuberculosis*. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) activity of all 4 complexes were determined (Tables 3 and 4). Overall, complex **3** was the most effective, inhibiting 9 out of the 12 organisms tested. Complex **3** also had the lowest MIC observed for all complexes tested, at 1.56 μ g/mL against *S. aureus*. Bactericidal activity was also observed against 7 out of the 12 organisms tested (Figure 4). The 2 organisms that did not have an MBC were both mycobacterial species, *M. abscessus* and *M. tuberculosis* (Figure 4 and 6). However, complex **3** was bacteriostatic against both species of mycobacteria inhibiting at a concentration of 12.5 μ g/mL and 100 μ g/mL, respectively. Complex **2** had similar inhibitory activity to complex **3**, however no activity was observed for *A. baumannii* or *E. coli* 1469 EBL (Table 3). Bactericidal activity for complex **2** was greatly reduced compared to complex **3** with an MBC observed for only *S. typhi* and *S. aureus*.

Complex **1** was less effective, only inhibiting *M. abscessus*, *M. tuberculosis*, *S. typhi* and *S. aureus*. No bactericidal activity was observed for *M. abscessus* but bactericidal activity was observed for *M. tuberculosis*, *S. tyhpi* and *S. aureus*. Arguably complex **4** was the least effective, with an MIC and MBC observed for only *S. aureus* and *M. tuberculosis* (Figure 6). However, *M. tuberculosis* is a major human pathogen that is often highly drug resistant. Therefore, complex **4** is still of great potential importance and could be effective against other pathogens not yet tested.

	Minimum Inhibitory Concentration (MIC) µg/mL			
Organism	Complex 1	Complex 2	Complex 3	Complex 4
<i>Acinetobacter baumannii</i> NCTC 12156	>100	>100	50	>100
	(>216.9 μM)	(>210.5 μM)	(94.5 μM)	(>191.2 μM)
Escherichia coli ATCC 11775	>100	100	50	>100
	(>216.9 μM)	(210.5 μM)	(94.5 μM)	(>191.2 μM)
Escherichia coli 1469 ESBL	>100	>100	50	>100
50	(>216.9 μM)	(>210.5 μM)	(94.5 μM)	(>191.2 μM)
Escherichia coli J53 2138E	>100	50	25	>100
	(>216.9 μM)	(105.2 μM)	(47.25 μM)	(>191.2 μM)
Escherichia coli J53 2140E	>100	100	25	>100
	(>216.9 μM)	(210.5 μM)	(47.25 μM)	(>191.2 μM)

Table 3. The minimum inhibitory concentrations observed for all organisms tested.

Klebsiella pneumoniae H467 KPC	>100	>100	>100	>100
	(>216.9 μM)	(>210.5 μM)	(<189 μM)	(>191.2 μM)
Mycobacterium abscessus NCTC	50	25	12.5	>100
13031				
	(108.4 μM)	(52.6 μM)	(23.6 µM)	(>191.2 μM)
Mycobacterium tuberculosis H37Rv	50	100	100	50
	(108.4 µM)	(210.5 µM)	(189 µM)	(95.6 µM)
Proteus mirabilis NCTC 8309	>100	>100	>100	>100
	(>216.9 μM)	(>210.5 μM)	(<189 μM)	(>191.2 μM)
<i>Pseudomonas aueruginosa</i> ATCC 10145	>100	>100	>100	>100
	(>216.9 µM)	(>210.5 μM)	(<189 μM)	(>191.2 μM)
Salmonella enterica serovar Typhi	50	25	6.25	>100
	(108.4 μM)	(52.6 μM)	(11.8 μM)	(>191.2 μM)
Staphylococcus aureus ATCC 29213	6.25	12.5	1.56	12.5
5	(13.5 μM)	(26.3 μM)	(2.94 μM)	(23.9 µM)

	Minimum Bactericidal Concentration (MBC) μg/mL			
Organism	Complex 1	Complex 2	Complex 3	Complex 4
Acinetobacter baumannii NCTC 12156	>100	>100	50	>100
	(>216.9 μM)	(>210.5 μM)	(94.5 μM)	(>191.2 μM)
Escherichia coli ATCC 11775	>100	>100	50	>100
	(>216.9 μM)	(>210.5 μM)	(94.5 μM)	(>191.2 μM)
Escherichia coli 1469 ESBL	>100	>100	50	>100
	(>216.9 μM)	(>210.5 μM)	(94.5 μM)	(>191.2 μM)
Escherichia coli J53 2138E	>100	>100	25	>100
	(>216.9 μM)	(>210.5 μM)	(47.25 μM)	(>191.2 μM)
Escherichia coli J53 2140E	>100	>100	25	>100
	(>216.9 μM)	(>210.5 μM)	(47.25 μM)	(>191.2 μM)
Klebsiella pneumoniae H467 KPC	>100	>100	>100	>100
30	(>216.9 μM)	(>210.5 μM)	(<189 µM)	(>191.2 μM)
<i>Mycobacterium abscessus</i> NCTC 13031	>100	>100	>100	>100
	(>216.9 μM)	(>210.5 μM)	(<189 µM)	(>191.2 μM)
Mycobacterium tuberculosis H37Rv	50	>100	>100	50
	(108.4 μM)	(>210.5 μM)	(<189 μM)	(95.6 μM)

 Table 4. The minimum bactericidal concentrations observed for all organisms tested.

Proteus mirabilis NCTC 8309	>100	>100	>100	>100
	(>216.9	(>210.5	(<189 µM)	(>191.2
	μM)	μM)		μM)
Pseudomonas aueruginosa ATCC	>100	>100	>100	>100
10145				
	(>216.9	(>210.5	(<189 µM)	(>191.2
	μM)	μM)		μM)
Salmonella enterica serovar Typhi	50	25	6.25	>100
	(108.4 µM)	(52.6 μM)	(11.8 µM)	(>191.2
		\$		μM)
Staphylococcus aureus ATCC 29213	12.5	12.5	3.125	50
	(27.11 μM)	(26.3 μM)	(5.9 μM)	(95.6 μM)




Figure 4 – The minimum bactericidal concentrations (MBC) for complex 3 identified by absence of growth. MBCs were defined by minimum concentration at which an absence of bacterial growth was observed after exposure to complex 3. A, *Acinetobacter baumannii* ATCC 12156 had an MBC of 50 μg/mL (n=3). B, *Escherichia coli* ATCC 11775 and C, *E. coli* ESBL had an MBC of 50 μg/mL (n=3). D, *E. coli* 2138E and E, *E. coli* 2140E both had MBCs of 25 μg/mL (n=3). F, *Salmonella enterica* serovar

Typhi had an MBC of 6.25 μg/mL (n=3). G, *Staphylococcus aureus* exhibited an MBC of 3.125 μg/mL (n=3). H, plate map showing concentrations of complex 3.

Growth curve data was obtained for *M. abscessus* (Figure 5) and analysed with an ANOVA. A significant difference between the different concentrations and controls was observed for complexes **1**, **2** and **3** with P values of <0.0001 for all three complexes. No significant difference between concentrations and control were observed for complex **4**. A multiple comparison was conducted for complexes **1**, **2** and **3**, which identified a significant difference between all concentrations and control (P value <0.0001) for all, apart from complex **1** at 3.125 μg/mL and the *M. abscessus* only control (P value 0.0064). This identifies that complexes **1**, **2** and **3** are bacteriostatic against *M. abscessus* and have a significant impact on the growth.




Figure 5 – Spectrophotometric growth curves of *Mycobacterium abscessus* with complexes 1 – 4 showing bacteriostatic activity. (1) Activity of complex 1 against *M. abscessus* identifying the minimum inhibitory concentration (MIC) as 50 µg/mL (n=3). A one-way ANOVA was used on endpoint data and identified a significant difference between all concentrations and the control (p value <0.0001), apart from 3.125 µg/mL (p value 0.0064). (2) Complex 2 exhibited increased activity, with an MIC of 25 µg/mL (n=3). All concentrations were significantly different to the growth of *M. abscessus* only (p value <0.0001). (3) Complex 3 was the most effective of the complexes tested, inhibiting *M. abscessus* at 12.5 µg/mL (n=3). All concentrations impacted the growth of *M. abscessus* significantly (p value <0.0001). (4) Complex 4 had no MIC observed and did not significantly impact the growth of *M. abscessus* (n=3) (p value 0.2960).




Figure 6 – Minimum Inhibitory Concentrations (MIC) (upper) and Minimum Bactericidal Concentrations (MBC) (lower) of *Mycobacterium tuberculosis* with complexes 1 – 4. (MBC images contrast adjusted to emphasise growth vs no growth). (1) Complex 1 shows an MIC with resazurin of 50 µg/mL and an MBC on solid agar of 50 µg/mL (n=3). (2) Complex 2 shows an MIC with resazurin of 100 µg/mL and no MBC on solid agar (>100 µg/mL) (n=3). (3) Complex 3 shows an MIC with resazurin of 100 µg/mL and no MBC on solid agar (>100 µg/mL) (n=3).(4) Complex 4 shows an MIC with resazurin of 50 µg/mL and an MBC on solid agar of 50 µg/mL (n=3).

All four of the complexes inhibited a variety of microorganisms tested, with complex **3** being the most effective. The Gram-positive *S. aureus* was the most effected organism with the lowest MIC and MBC for all of the complexes tested, as well as being the only one, other than *M. tuberculosis*, affected by complex **4**. Growth of *M. tuberculosis* was also inhibited by each complex, but at higher concentrations than for *S. aureus*. However, unlike *S. aureus*, complexes **2** and **3** had no bactericidal activity against *M. tuberculosis*. *M. abscessus* was largely inhibited by three out of the four complexes but had no bactericidal activity. A range of activity was identified for the Gram-negative organisms *E. coli* and *S. typhi* against complexes **1**, **2** and **3**, however no activity was observed for *Proteus mirabilis, Pseudomonas aeruginosa* or *Klebsiella pneumonia*.

Conclusions

In conclusion, four half-sandwich metal complexes containing a bioactive indole moiety were synthesised and characterised. They were progressed to *in vitro* screening to gain a first estimation of their cytotoxicity profile. The complexes only show moderate toxicity against A2780 ovarian cancer, A2780 cisplatin resistant, and PNT2 cell lines. As such, the bactericidal activity of the four compounds was investigated against several drug resistant isolates of Gram negative *Escherichia coli* and *Salmonella enterica* serovar *Typhi* as well as against isolates of Gram positive bacteria.

All complexes showed growth inhibition and bactericidal activity against a variety of bacteria, including the notable pathogens *M. tuberculosis, M. abscessus* and *E. coli*. Complexes **2** and **3** exhibit the most promising antibacterial activities, having the lowest minimum inhibitory concentrations and exhibiting bactericidal activity. It appears that steric hindrance of the R group on the indole has an influence on the aquation rate, the cytotoxicity, and the antibacterial properties, which will be

confirmed/infirmed by future determination of the antibacterial mechanism of action. This series shows significant promise for further hit-to-lead medicinal chemistry, and future work will include further cytotoxicity studies, collection of *in vivo* data and mechanisms of action elucidation (target identification).

Materials and methods

Hydrated metallic chlorides were purchased from Precious Metals Online. All other chemicals were purchased from Sigma-Aldrich (UK). Non-dried solvents were purchased from Fischer Scientific and used as received. Dichloromethane, tetrahydrofuran and toluene were dried over molecular sieves (3 Å). All compounds were prepared under a purified dinitrogen atmosphere using standard Schlenk and vacuum line techniques, unless otherwise specified. pH* was adjusted using EDT direction non-glass pocket pH meter with an ISFET silicon chip pH sensor. pH* values (pH readings without correction for the effect of deuterium) of NMR samples were adjusted using KOD solutions in D₂O. All NMR spectra were recorded on a 400 MHz Bruker Spectrospin spectrometer using 5 mm NMR tubes. Data processing was carried out using TOPSPIN 4.0.9 (Bruker U.K. Ltd.). Deuterated solvents were purchased from Goss Scientific Instrument. ¹H NMR chemical shifts were internally referenced to TMS *via* residual solvent peaks DMSO ($\delta = 2.52$ ppm), CHCl₃ ($\delta = 7.26$ ppm), acetone ($\delta = 2.05$ ppm), THF ($\delta = 1.72$ ppm) or MeOD ($\delta = 3.31$ ppm). All UV-Vis spectra were recorded with Agilent 60 Cary UV-Vis spectrophotometer. Ruthenium dimer [(*p*-cym)RuCl₂]₂ was synthesised using an Anton Paar microwave synthesis reactor (Monowave 300) and a 20 mL microwave vial equipped with a magnetic stirring bar.

Roswell Park Memorial Institute (RPMI) 1640 medium, foetal bovine serum (FBS), penicillin and streptomycin, phosphate-buffered saline (PBS, pH 7.4), and other tissue culture reagents were purchased from Gibco (Thermo Fisher Scientific, UK). Cell lines were provided by the Institute of Cancer Therapeutics, University of Bradford. Cells were incubated in a ThermoScientific HERAcell 150 incubator and observed under a Nikon ECLIPSE TS100 Microscope.


Bacterial culture

All chemicals and reagents were obtained from Sigma-Aldrich or Fisher Scientific, unless otherwise stated. The media used for *Mycobacterium abscessus* NCTC 13031 and *Mycobacterium tuberculosis* H37Rv was Middlebrook 7H9 broth with the addition of Albumin-Dextrose-Catalase (ADC) supplement (10%) and Tween80 (0.05%) and Middlebrook 7H11 agar with Oleic acid-Albumin-Dextrose-Catalase (OADC) supplement (10%). The media used for all other organisms (*Escherichia coli* ATCC 11775, *E. coli* 1469 ESBL, *E. coli* J53 2138E, *E. coli* J53 2140E, *Klebsiella pneumonia* H467 KPC, *Proteus mirabilis* NCTC 8309, *Pseudomonas aeruginosa* ATCC 10145, *Salmonella enterica* serovar *Typhi*, *Staphylococcus aureus* ATCC 29213) was nutrient broth and nutrient agar. Prior to testing, all organisms were grown in broth to log phase at 37 °C with orbital shaking at 180 rpm. For *M. abscessus* this was 72 h, for *M. tuberculosis* this was 168 h and all other organisms 24 h.

Synthesis and characterisation

[Methyl indole-2-carboxylate] (L2). 1-*H*-indole-2-carboxylic acid (3.0 g, 18.6 mmol) was added to a round-bottom flask (100 mL) and dissolved in methanol (30 mL). Concentrated sulphuric acid (1.5 mL, 28.0 mmol) was added to the mixture and subsequently heated to reflux for 2 h. Then, the

solvent was removed under reduced pressure, and the crude was dissolved in ethyl acetate (6 mL), and subsequently extracted with a saturated solution of NaHCO₃ (3 x 30 mL). The organic phases were combined and dried over MgSO₄ and filtered. The filtrate was evaporated under vacuum to afford a light-brown powder (4.3 g, 93%). The synthesis and characterisation are in accordance with the literature.⁵⁰




¹H NMR (DMSO-d₆, 400 MHz): δ = 11.91 (1H, s, H1), 7.65 (1H, d, ${}^{3}J_{H-H}$ = 8.0 Hz, H4), 7.45 (1H, d, ${}^{3}J_{H-H}$ = 8.3 Hz, H7), 7.26 (1H, dd, ${}^{3}J_{H-H}$ = 6.8 and 8.0 Hz, H6), 7.15 (1H, m, H3), 7.07 (1H, dd, ${}^{3}J_{H-H}$ = 6.8 and 8.0 Hz, H5), 3.87 ppm (3H, s, H11).

¹³C{¹H} NMR (DMSO-d₆, 101 MHz): δ = 161.8 (C10), 137.4 (C2), 127.0 (C8 or C9), 126.7 (C8 or C9), 124.7 (C6), 122.1 (C4), 120.2 (C5), 112.6 (C7), 107.8 (C3), 51.8 ppm (C11).

HRMS (ESI+): m/z calc. for $C_{10}H_{10}NO_2 [M + H]^+$ 176.0667; found 176.0702.

[Ethyl indole-2-carboxylate] (L3). The procedure used to prepare L2 was followed with 30 mL of ethanol and 18.6 mmol of 1-*H*-indole-2-carboxylic acid. The pure compound L3 was obtained as a white powder (4.1 g, 91%). The synthesis and characterisation are in accordance with the literature.⁵¹




¹H NMR (DMSO-d₆, 400 MHz): δ = 11.86 (1H, s, H1), 7.65 (1H, d, ³J_{H-H} = 8.0 Hz, H4), 7.45 (1H, d, ³J_{H-H} = 8.4 Hz, H7), 7.25 (1H, dd, ³J_{H-H} = 7.2 and 8.4 Hz, H6), 7.14 (1H, m, H3), 7.07 (1H, dd, ³J_{H-H} = 7.2 and 8.0 Hz, H5), 4.34 (2H, q, ³J_{H-H} = 7.1 Hz, H11), 1.34 ppm (3H, t, ³J_{H-H} = 7.0 Hz, H12).

¹³C{¹H} NMR (DMSO-d₆, 101 MHz): δ = 161.3 (C10), 137.4 (C2), 127.3 (C8 or C9), 126.7 (C8 or C9), 124.6 (C6), 122.1 (C4), 120.2 (C5), 112.6 (C7), 107.7 (C3), 60.4 (C11), 14.3 ppm (C12).

HRMS (ESI+): m/z calc. for $C_{10}H_{10}NO_2$ [M + H]⁺ 190.0823; found 190.08564.

[Cyclohexyl indole-2-carboxylate] (L4). The procedure used to prepare **L3** was followed with 10 mL of cyclohexanol and 18.6 mmol of 1-*H*-indole-2-carboxylic acid. The pure compound **L4** was obtained as a light-brown powder (4 g, 91%).




¹H NMR (DMSO-d₆, 400 MHz): δ = 11.72 (1H, s, H1), 7.55 (1H, d, ³J_{H-H} = 8.0 Hz, H4), 7.37 (1H, d, ³J_{H-H} = 8.4 Hz, H7), 7.16 (1H, dd, ³J_{H-H} = 7.2 and 7.8 Hz, H6), 7.05 (1H, m, H3), 6.98 (1H, dd, ³J_{H-H} = 7.0 and 7.6 Hz, H5), 4.86 (1H, m, H11), 1.86 – 1.15 ppm (10H, br, H_{cyclohexane}).

¹³C{¹H} NMR (DMSO-d₆, 101 MHz): δ = 160.8 (C10), 137.4 (C2), 127.7 (C8 or C9), 126.8 (C8 or C9), 124.6 (C6), 122.0 (C4), 120.1 (C5), 112.6 (C7), 107.7 (C3), 72.3 (C11), 31.2 (C12, C16), 25.0 (C14), 23.1 ppm (C13, C15).

HRMS (ESI+): m/z calc. for $C_{15}H_{18}NO_2$ [M + H]⁺ 244.1293; found 245.13568.

[Phenyl indole-2-carboxylate] (L5). 1-*H*-indole-2-carboxylic acid (5.0 g, 31.0 mmol) was added to a round-bottom flask (100 mL). Phenol (2.92 g, 31.0 mmol), *N*,*N*-dimethyl-4-aminopyridine (DMAP, 1 g, 8.19 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 8.0 g, 51.53 mmol) and dry dichloromethane (60 mL) were added to the mixture and subsequently heated to reflux for 24 h. Then, the crude solution was quenched with a saturated aqueous solution of NaHCO₃ and extracted with H₂O (3 x 30 mL). The organic phases were combined and dried over MgSO₄ and filtered. The filtrate was evaporated under vacuum to afford a white powder (2.8 g, 37%). The synthesis and characterisation are in accordance with the literature.⁵²




¹H NMR (DMSO-d₆, 400 MHz): δ = 12.15 (1H, s, H1), 7.72 (1H, d, ³J_{H-H} = 8.0 Hz, H4), 7.49 (3H, dd, ³J_{H-H} = 8.8 and 9.2 Hz, H7, H13 and H15.), 7.41 (1H, m, H3), 7.32 (4H, m, H6, H12, H14 and H16), 7.13 ppm (1H, dd, ³J_{H-H} = 7.4 and 7.6Hz, H5).

¹³C{¹H} NMR (DMSO-d₆, 101 MHz): δ = 159.8 (C10), 150.3 (C11), 137.8 (C2), 129.6 (C13 and C15), 126.7 (C8 or C9), 126.2 (C8 or C9), 126.0 (C6 or C14), 125.2 (C6 or C14), 122.3 (C4), 122.0 (C12 and C16), 120.5 (C5), 112.7 (C7), 109.5 ppm (C3).

HRMS (ESI+): m/z calc. for $C_{15}H_{12}NO_2$ [M + H]⁺ 238.0823; found 238.08532.

[Methyl indole-2-thionoester] (L6). L2 (250 mg 1.43 mmol), and Lawesson's reagent (693 mg, 1.7 mmol) were added to a round-bottom flask and dissolved in toluene (35 mL). The mixture was refluxed for 6 days. The solution was cooled down and toluene was removed under reduced pressure. The crude was dissolved in ethyl acetate and extracted first with an aqueous saturated solution of NaHCO₃, and then with brine, and dried over MgSO₄ and filtered. The combined organic phases were brought to dryness, leaving a bright yellow oil, which was purified by column chromatography (hexane/ethyl acetate, 80:20 (v/v)). The solvent was removed under vacuum to give a bright yellow solid (203 mg, 74%).




¹H NMR (DMSO-d₆, 400 MHz): δ = 11.75 (1H, s, H1), 7.67 (1H, d, ${}^{3}J_{H-H}$ = 8.4 Hz, H4), 7.48 (1H, d, ${}^{3}J_{H-H}$ = 8.4 Hz, H7), 7.28 (2H, m, H3 and H6), 7.07 (1H, dd, ${}^{3}J_{H-H}$ = 7.6 and 8.0 Hz, H5), 4.24 ppm (3H, s, H11).

¹³C{¹H} NMR (DMSO-d₆, 101 MHz): δ = 201.7 (C10), 138.4 (C2), 136.4 (C8 or C9), 126.9 (C8 or C9), 125.6 (C6), 122.6 (C4), 120.6 (C5), 112.9 (C7), 107.2 (C3), 58.4 ppm (C11).

HRMS (ESI+): m/z calc. for $C_{10}H_{10}NOS [M + H]^+$ 192.0483; found 192.0475.

[Ethyl indole-2-thionoester] (L7). The procedure used to prepare L6 was followed with 250 mg (1.3 mmol) of L3 and Lawesson's reagent (623 mg, 1.57 mmol) and refluxed for 6 days. The pure compound L7 was obtained as a bright yellow solid (220 mg, 81%).




¹H NMR (DMSO-d₆, 400 MHz): δ = 11.69 (1H, s, H1), 7.67 (1H, d, ³J_{H-H} = 8.4 Hz, H4), 7.49 (1H, d, ³J_{H-H} = 8.4 Hz, H7), 7.28 (2H, m, H3 and H6), 7.07 (1H, dd, ³J_{H-H} = 7.6 and 8.0Hz, H5), 4.70 (2H, q, ³J_{H-H} = 7.1 Hz, H11), 1.47 ppm (3H, t, ³J_{H-H} = 7.0 Hz, H12).

¹³C{¹H} NMR (DMSO-d₆, 101 MHz): δ = 201.0 (C10), 138.3 (C2), 136.6 (C8 or C9), 126.9 (C8 or C9), 125.6 (C6), 122.6 (C4), 120.6 (C5), 112.9 (C7), 107.1 (C3), 67.4 (C11), 13.7 ppm (C12).

HRMS (ESI+): m/z calc. for $C_{11}H_{12}NOS [M + H]^+ 206.0595$; found 206.0632.

[Cyclohexyl indole-2-thionoester] (L8). The procedure used to prepare **L6** was followed with 250 mg (1.0 mmol) of **L4** and Lawesson's Reagent (499 mg, 1.23 mmol) and refluxed for 4 days. The pure compound **L8** was obtained as a bright yellow solid (190 mg, 71%).




¹H NMR (DMSO-d₆, 400 MHz): δ = 11.62 (1H, s, H1), 7.67 (1H, d, ${}^{3}J_{H-H}$ = 8.0 Hz, H4), 7.49 (1H, d, ${}^{3}J_{H-H}$ = 8.0 Hz, H7), 7.28 (1H, dd, ${}^{3}J_{H-H}$ = 7.8 and 8.4 Hz, H6), 7.25 (1H, m, H3), 7.07 (1H,dd, ${}^{3}J_{H-H}$ = 7.6 and 8.0 Hz, H5), 5.58 (1H, m, H11), 2.05 – 1.33 ppm (10H, br, H_{cyclohexane}).

¹³C{¹H} NMR (DMSO-d₆, 101 MHz): δ = 200.0 (C10), 138.3 (C2), 136.9 (C8 or C9), 126.9 (C8 or C9), 125.5 (C6), 122.6 (C4), 120.6 (C5), 112.9 (C7), 107.0 (C3), 78.7 (C11), 30.4 (C12, C16), 24.9 (C14), 23.0 ppm (C13, C15).

HRMS (ESI+): m/z calc. for $C_{15}H_{18}NOS [M + H]^+$ 260.1064; found 260.1099.

[Phenyl indole-2-thionoester] (L9): The procedure used to prepare L6 was followed with 250 mg (1.1 mmol) of L5 and Lawesson's Reagent (511 mg, 1.26 mmol) and refluxed for 8 days. The pure compound L9 was obtained as a bright yellow solid (100 mg, 37%).




¹H NMR (DMSO-d₆, 400 MHz): δ = 11.96 (1H, s, H1), 7.72 (1H, d, ${}^{3}J_{H-H}$ = 8.0 Hz, H4), 7.55 – 7.48 (4H, m, H3, H7, H13 and H15), 7.37 – 7.32 (2H, m, H6 and H14), 7.24 (2H, d, ${}^{3}J_{H-H}$ = 7.6 Hz, H12 and H16), 7.11 ppm (1H, dd, ${}^{3}J_{H-H}$ = 7.6 and 8.0 Hz, H5).

¹³C{¹H} NMR (DMSO-d₆, 101 MHz): δ = 200.0 (C10), 153.7 (C11), 138.9 (C2), 136.4 (C9 or C9), 129.7 (C13 and C15), 127.0 (C8 or C9, 126.5 (C6 or C14), 126.3 (C6 or C14), 122.9 (C4), 122.4 (C12 and C16), 120.9 (C5), 113.0 (C7), 108.9 ppm (C3).

HRMS (ESI+): m/z calc. for $C_{15}H_{12}NOS [M + H]^+ 254.0595$; found 254.0631.

[(p-cym)RuCl(methyl indole-2-thionoester)] (1).

Ruthenium dimer $[(p-cym)RuCl_2]_2$ (70 mg, 0.11 mmol) and L6 (46 mg, 0.24 mmol) were placed in a 50 mL round-bottom flask and dissolved in 15 mL of dry dichloromethane. Once dissolved, 62 µL of dry triethylamine (0.46 mmol) were added to the mixture. The bright orange mixture was stirred under nitrogen overnight at 25 °C, until a brown solution was obtained. The crude was extracted with an aqueous solution of 0.1 M HCl (3 x 10 mL) and the combined organic phases were dried over MgSO₄ and filtered. The product was purified by column chromatography (ethyl acetate/hexane 60:40 (v/v)) and recrystallised in dichloromethane/hexane to obtain a bright red solid (30 mg, 58%).




¹H NMR (CDCl₃, 400 MHz): δ = 7.59 (1H, d, ³J_{H-H} = 8.4 Hz, H13), 7.56 (1H, d, ³J_{H-H} = 8.4 Hz, H16), 7.22 (1H, dd, ³J_{H-H} = 6.8 and 8.0, H15), 7.07 (1H, s, H12), 6.96 (1H, dd, ³J_{H-H} = 6.8 and 8.0 Hz, H14), 5.83 (2H, q, ³J_{H-H} = 6.2 Hz, H3 and H4), 5.72 (1H, d, ³J_{H-H} = 5.8 Hz, H6), 5.58 (1H, d, ³J_{H-H} = 6.0 Hz, H5), 4.37 (3H, s, H20), 2.53 (1H, sept, ³J_{H-H} = 6.9 Hz, H8), 2.25 (3H, s, H1), 1.07 (3H, d, ³J_{H-H} = 6.9 Hz, H10), 0.92 ppm (3H, d, ³J_{H-H} = 6.9 Hz, H9).

¹³C{¹H} NMR (CDCl₃, 101 MHz): δ = 206.6 (C19), 152.0 (C11), 144.4 (C17 or C18), 130.9 (C17 or C18), 125.5 (C15), 124.5 (C13), 120.0 (C14), 116.8 (C16), 108.2 (C12), 103.0 (C7), 102.3 (C2), 85.9 (C6), 83.7 (C3 or C4), 83.2 (C3 or C4), 82.0 (C5), 60.1 (C20), 31.1 (C8), 23.0 (C10), 21.8 (C9), 19.0 ppm (C1).

HRMS (ESI+): m/z calc. for $C_{20}H_{22}NORuS$ [M - Cl]⁺ 426.0466; found 426.0452.

[(p-cym)RuCl(ethyl indole-2-thionoester)] (2).

Complex **2** was synthesised following the procedure of complex **1** with **L7** (50 mg, 0.24 mmol). The pure compound **2** was obtained as a bright red solid (30 mg, 56%).




¹H NMR (CDCl₃, 400 MHz): δ = 7.58 (2H, m, H13, H16), 7.21 (1H, dd, ³J_{H-H} = 6.8 and 8.0 Hz, H15), 7.08 (1H, s, H12), 6.96 (1H, dd, ³J_{H-H} = 6.8 and 7.6 Hz, H14), 5.82 (2H, q, ³J_{H-H} = 6.0 Hz, H3, H4), 5.71 (1H, d, ³J_{H-H} = 5.9 Hz, H6), 5.56 (1H, d, ³J_{H-H} = 5.9 Hz, H5), 4.74 (2H, q, ³J_{H-H} = 7.1 Hz, H20), 2.53 (1H, sept, ³J_{H-H} = 6.9 Hz, H8), 2.25 (3H, s, H1), 1.55 (3H, t, ³J_{H-H} = 7.0 Hz, H21), 1.07 (3H, d, ³J_{H-H} = 7.2 Hz, H10), 0.92 ppm (3H, d, ³J_{H-H} = 6.9 Hz, H9).

¹³C{¹H} NMR (CDCl₃, 101 MHz): δ = 205.8 (C19), 151.9 (C11), 144.5 (C17 or C18), 130.9 (C17 or C18), 125.3 (C15), 124.5 (C13), 119.9 (C14), 116.8 (C16), 108.0 (C12), 103.0 (C7), 102.1 (C2), 85.9 (C6), 83.7 (C3 or C4), 83.2 (C3 or C4), 82.0 (C5), 69.8 (C20), 31.1 (C8), 23.0 (C10), 21.8 (C9), 19.1 (C1), 14.4 ppm (C21).

HRMS (ESI+): m/z calc. for $C_{21}H_{24}NORuS [M - CI]^+ 440.0622$; found 440.0614.

[(p-cym)RuCl(cyclohexyl indole-2-thionoester)] (3).

Complex **3** was synthesised following the procedure of complex **1** with **L8** (62 mg, 0.24 mmol). The pure compound **3** was obtained as a bright red solid (39 mg, 65%).




¹H NMR (CDCl₃, 400 MHz): δ = 7.58 (2H, m, H13, H16), 7.21 (1H, dd, ³J_{H-H} = 6.8 and 8.0 Hz, H15), 7.07 (1H, s, H12), 6.95 (1H, dd, ³J_{H-H} = 6.8 and 7.6 Hz, H14), 5.80 (2H, m, H3, H4), 5.70 (1H, d, ³J_{H-H} = 6.0 Hz, H6), 5.55 (1H, d, ³J_{H-H} = 5.9 Hz, H5), 5.37 (1H, m, H20), 2.52 (1H, sept, ³J_{H-H} = 6.9 Hz, H8), 2.25 (3H, s, H1), 2.20 – 1.24 (10H, br, H_{cyclohexane}), 1.07 (3H, d, ³J_{H-H} = 7.0 Hz, H10), 0.93 ppm (3H, d, ³J_{H-H} = 7.0 Hz, H9).

¹³C{¹H} NMR (CDCl₃, 101 MHz): δ = 204.8 (C19), 151.8 (C11), 145.0 (C17 or C18), 130.8 (C17 or C18), 125.2 (C15), 124.4 (C13), 119.8 (C14), 116.8 (C16), 107.9 (C12), 103.0 (C7), 101.9 (C2), 85.9 (C6), 83.8 (C3 or C4), 83.3 (C3 or C4), 82.9 (C20), 82.0 (C5), 31.5 (CH_{2cyclohex}), 31.1 (C8), 25.4 (CH_{2cyclohex}), 23.7 (2CH_{2cyclohex}), 23.6 (CH_{2cyclohex}), 22.9 (C10), 21.8 (C9), 19.0 ppm (C1).

HRMS (ESI+): m/z calc. for C₂₅H₃₀NORuS [M - Cl]⁺ 494.1092; found 494.1088.

[(p-cym)RuCl(phenyl indole-2-thionoester)] (4).

Complex **4** was synthesised following the procedure of complex **1** with **L9** (61 mg, 0.24 mmol). The pure compound **4** was obtained as a bright red solid (31 mg, 51%).



¹H NMR (CDCl₃, 400 MHz): δ = 7.63 (1H, d, ³J_{H-H} = 8.2 Hz, H13), 7.57 (1H, d, ³J_{H-H} = 8.7 Hz, H16), 7.48 (2H, m, H22 and H24), 7.37 (1H, t, ³J_{H-H} = 7.4 Hz, H23), 7.29 – 7.21 (4H, m, H12, H15, H21 and H25), 6.99 (1H, dd, ³J_{H-H} = 6.4 and 8.0 Hz, H14), 5.83 (1H, d, ³J_{H-H} = 6.0 Hz, H4), 5.80 (1H, d, ³J_{H-H} = 6.0 Hz, H3), 5.64 (1H, d, ³J_{H-H} = 5.9 Hz, H6), 5.49 (1H, d, ³J_{H-H} = 5.9 Hz, H5), 2.49 (1H, sept, ³J_{H-H} = 6.9 Hz, H8), 2.24 (3H, s, H1), 1.06 (3H, d, ⁴J_{H-H} = 7.0 Hz, H10), 0.94 ppm (3H, d, ⁴J_{H-H} = 7.0 Hz, H9).

¹³C{¹H} NMR (CDCl₃, 101 MHz): δ = 204.9 (C19), 154.8 (C20), 153.0 (C11), 144.8 (C17 or C18), 131.1 (C17 or C18), 130.0 (C22 and C24), 127.2 (C23), 126.2 (C15), 124.9 (C13), 122.0 (C21 and C25), 120.4 (C14), 116.9 (C16), 109.5 (C12), 103.3 (C7), 102.1 (C2), 85.9 (C6), 83.9 (C4), 83.5 (C3), 81.8 (C5), 31.1 (C8), 22.8 (C10), 21.9 (C9), 19.0 ppm (C1).

HRMS (ESI+): m/z calc. for C₂₅H₂₄NORuS [M - Cl]⁺ 488.0622; found 488.0617.

Solution chemistry

Stability determination: Complexes 1 - 4 were dissolved in MeOD (2.2 mM) and diluted to a final concentration of 1.1 mM with either MeOD or D₂O. ¹H NMR spectra were recorded at t \leq 10 min, 12 h and 24 h.

pKa determination: Complexes 1 - 4 were dissolved in acetonitrile/H₂O 6:94 (v/v) and UV-Vis spectra of the sample were recorded increasing the pH from 7 to 12. pKa value of each complex was determined using Origin 2019 by plotting the absorbance against the pH.

Hydrolysis rate: Complexes 1 - 4 were dissolved in DMSO/RPMI 1:1 (v/v) (3 x 10⁻⁵ M) at room temperature and UV-Vis spectra of the samples were recorded at different times between t \leq 10 min and 24 h. The dissociation constant values were calculated using Origin 2019 by plotting the absorbance against the time at fixed wavelength.

Chemosensitivity Assays

In vitro chemosensitivity tests were performed against A2780, A2780cisR and PNT2 cells. Cancer cell lines were routinely maintained as monolayer cultures in RPMI medium supplemented with 10% foetal calf serum, penicillin (100 I.U./mL) and streptomycin (100 μ g/mL), sodium pyruvate (1 mM) and L-glutamine (2 mM). For chemosensitivity studies, cells were incubated in 96-well plates at a concentration of 7.5 × 10³ cells per well and the plates were incubated for 24 h at 37 °C and a 5% CO₂ humidified atmosphere prior to drug exposure.

Complexes were dissolved in dimethylsulfoxide (DMSO) to provide stock solutions which were further diluted with media to provide a range of final concentrations. Drug-media solutions were

added to cells (the final concentration of DMSO was less than 1% (v/v) in all cases) and incubated for 24 h at 37 °C and 5% CO₂ humidified atmosphere. The drug-media was removed from the wells and the cells were washed with PBS (100 μ L, twice), and 100 μ L of complete fresh media were added to each well. The plates were further incubated for 48 h at 37 °C in a 5% CO₂ humidified atmosphere to allow for a period of recovery. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (20 μ L, 2.5 mg/mL) was added to each well and incubated for 2 h at 37 °C and 5% CO₂ humidified atmosphere. All solutions were then removed and 100 μ L of DMSO was added to each well in order to dissolve the purple formazan crystals. A Thermo Scientific Multiskan EX microplate photometer was used to measure the absorbance in each well at 570 nm. Cell survival was determined as the absorbance of treated cells divided by the absorbance of controls and expressed as a percentage. The IC₅₀ values were determined from plots of % survival against drug concentration. Each experiment was repeated in triplicates of triplicates and a mean value was obtained and stated as IC₅₀ (μ M) ± SD. Cisplatin was also used as a positive control.

Bacterial susceptibility testing

A broth microdilution assay was used to determine antimicrobial activity of the compounds. Briefly, complexes 1-4 were made up to a stock solution of 10 mg/mL in DMSO (dimethylsulphoxide) and serially diluted in 96 well plates to final concentrations of 100 μ g/mL, 50 μ g/mL, 25 μ g/mL, 12.5 μ g/mL, 6.25 μ g/mL and 3.125 μ g/mL. All bacterial suspensions (except *M. tuberculosis*) were adjusted to an optical density (OD₆₀₀) of 0.1 prior to inoculation. An initial spectrophotometric read was taken using a Biotek EL808 plate reader at 570 nm. The plates were then incubated at 37 °C and read every 24 h for the length of the assay (*M. abscessus* = 96 h, all other organisms = 24 h). Once the spectrophotometric assays were complete, 5 μ L of each well was plated out onto appropriate agar and incubated at 37 °C for 24-48 h to check for bactericidal activity. All data was processed through GraphPad Prism 8.

M. tuberculosis was assessed by addition of OD_{600} adjusted culture (OD_{600} =0.001) to experimental wells containing serially diluted complexes 1-4 (as previously described). Plates were incubated for 168 h at 37 °C, before 5 µL of each experimental well was plated onto Middlebrook 7H11 agar with OADC. These agar plates were incubated at 37 °C for 312 h. The drug containing 96-well plates were also additionally incubated for a further 240 h at 37 °C, after which resazurin (0.0025%) was added and plates were incubated at 37 °C for a final 24 h. Minimum inhibitory concentrations were determined by conversion of resazurin to resorufin. Minimum bactericidal concentrations were determined by the lowest concentration in which no growth was visibly seen on the solid agar plates.

Author Contributions

Conceptualization, Anaïs Pitto-Barry, Nicolas P. E. Barry and Jonathan A. G. Cox; Formal analysis, Laia Rafols, Joan Soldevila Barreda, Anaïs Pitto-Barry, Colin Seaton, James Harrison, Victoria C. Nolan; Funding acquisition, Nicolas P. E. Barry and Jonathan A. G. Cox; Methodology, Laia Rafols, Joan Soldevila Barreda, Helen Sendron, Maria Azmanova, Colin Seaton; Supervision, Joan Soldevila Barreda, Victoria C. Nolan, Danielle L. Timms, James Harrison, Anaïs Pitto-Barry, Nicolas P. E. Barry and Jonathan A. G. Cox: Nethodology, Laia Rafols, Joan Soldevila Barreda, Helen Sendron, Maria Azmanova, Colin Seaton; Supervision, Joan Soldevila Barreda, Victoria C. Nolan, Danielle L. Timms, James Harrison, Anaïs Pitto-Barry, Nicolas P. E. Barry and Jonathan A. G. Cox. All authors have read and agreed to the published version of the manuscript.

Declaration of interests

Jonathan Cox has patent #International PCT Application No. PCT/GB2021/050471 pending to Aston University

Acknowledgements

N.P.E.B. acknowledges the support of the Royal Society (University Research Fellowship No. UF150295 to N.P.E.B.), the University of Bradford, and by the Academy of Medical Sciences/the Wellcome Trust/the Government Department of Business, Energy and Industrial Strategy/the British Heart Foundation Springboard Award [SBF003\1170 to N.P.E.B.].

J.A.G.C. is grateful to the Academy of Medical Sciences, Global Challenges Research Fund, Birmingham Women's and Children's Hospital Charity Research Foundation and Give A Child Health Fund for their continued support of the Mycobacterial Research Group at Aston University. This research was funded by the Academy of Medical Sciences/the British Heart Foundation/the Government Department of Business, Energy and Industrial Strategy/Global Challenges Research Fund/the Wellcome Trust Springboard Award [SBF003\1088]. VCN is supported with a PhD Studentship jointly funded by Give A Child Health Fund and Aston University.

References

1. <u>https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance</u>.

2. Wang, T. Z.; Kodiyanplakkal, R. P. L.; Calfee, D. P., Antimicrobial resistance in nephrology. *Nature Reviews Nephrology* **2019**, *15*, 463-481.

3. Cox, J. A. G.; Worthington, T., The 'Antibiotic Apocalypse' – Scaremongering or Scientific Reporting? *Trends Microbiol.* **2017**, *25*, 167-169.

4. Barry, N. P. E.; Sadler, P. J., Exploration of the medical periodic table: towards new targets. *Chem. Commun.* **2013**, *49*, 5106-5131.

5. Barry, N. P. E.; Sadler, P. J., 100 years of metal coordination chemistry: from Alfred Werner to anticancer metallodrugs. *Pure Appl. Chem.* **2014**, *86*, 1897-1910.

6. Silva, M. J. S. A.; Gois, P. M. P.; Gasser, G., Unveiling the Potential of Transition Metal Complexes for Medicine: Translational in Situ Activation of Metal-Based Drugs from Bench to in Vivo Applications. *ChemBioChem n/a* (n/a).

7. Biancalana, L.; Batchelor, L. K.; Pereira, S. A. P.; Tseng, P.-J.; Zacchini, S.; Pampaloni, G.; Saraiva, L. M. F. S.; Dyson, P. J.; Marchetti, F., Bis-conjugation of Bioactive Molecules to Cisplatin-like Complexes through (2,2'-Bipyridine)-4,4'-Dicarboxylic Acid with Optimal Cytotoxicity Profile Provided by the Combination Ethacrynic Acid/Flurbiprofen. *Chem. Eur. J* **2020**, *26*, 17525-17535.

8. Farley, S. J.; Salassa, L.; Pizarro, A. M.; Sadler, P. J., Photoactive Platinum(II) Azopyridine Complexes. *Photochem. Photobiol. n/a* (n/a).

9. Hanif, M.; Arshad, J.; Astin, J. W.; Rana, Z.; Zafar, A.; Movassaghi, S.; Leung, E.; Patel, K.; Söhnel, T.; Reynisson, J.; Sarojini, V.; Rosengren, R. J.; Jamieson, S. M. F.; Hartinger, C. G., A Multitargeted Approach: Organorhodium Anticancer Agent Based on Vorinostat as a Potent Histone Deacetylase Inhibitor. *Angew. Chem. Int. Ed.* **2020**, *59*, 14609-14614.

10. Rafols, L.; Josa, D.; Aguilà, D.; Barrios, L.; Roubeau, O.; Cirera, J.; Soto-Cerrato, V.; Pérez-Tomás, R.; Martínez, M.; Grabulosa, A.; Gamez, P., Piano-Stool Ruthenium(II) Complexes with Delayed Cytotoxic Activity: Origin of the Lag Time. *Inorg. Chem.* **2021**.

11. Anthony, E. J.; Bolitho, E. M.; Bridgewater, H. E.; Carter, O. W. L.; Donnelly, J. M.; Imberti, C.; Lant, E. C.; Lermyte, F.; Needham, R. J.; Palau, M.; Sadler, P. J.; Shi, H.; Wang, F.-X.; Zhang, W.-Y.; Zhang, Z., Metallodrugs are unique: opportunities and challenges of discovery and development. *Chem. Sci.* **2020**, *11*, 12888-12917.

12. Golbaghi, G.; Groleau, M.-C.; López de los Santos, Y.; Doucet, N.; Déziel, E.; Castonguay, A., Cationic Rull Cyclopentadienyl Complexes with Antifungal Activity against Several Candida Species. *ChemBioChem* **2020**, *21*, 3112-3119.

13. Minori, K.; Rosa, L. B.; Bonsignore, R.; Casini, A.; Miguel, D. C., Comparing the Antileishmanial Activity of Gold(I) and Gold(III) Compounds in L. amazonensis and L. braziliensis in Vitro. *ChemMedChem* **2020**, *15*, 2146-2150.

14. Melis, D. R.; Hsiao, C.-Y.; Combrinck, J. M.; Wiesner, L.; Smith, G. S., Subcellular Localisation of a Quinoline-Containing Fluorescent Cyclometallated IrIII Complex in Plasmodium falciparum. *ChemBioChem* **2021**, *22*, 1568-1572.

15. Yuan, S.; Wang, R.; Chan, J. F.-W.; Zhang, A. J.; Cheng, T.; Chik, K. K.-H.; Ye, Z.-W.; Wang, S.; Lee, A. C.-Y.; Jin, L.; Li, H.; Jin, D.-Y.; Yuen, K.-Y.; Sun, H., Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. *Nat. Microbiol.* **2020**, *5*, 1439-1448.

16. Zhang, J.; Pitto-Barry, A.; Shang, L.; Barry, N. P. E., Anti-inflammatory activity of electrondeficient organometallics. *R. Soc. Open Sci.* **2017**, *4*, 170786.

17. Gambino, D.; Otero Á, L., Metal Compounds in the Development of Antiparasitic Agents: Rational Design from Basic Chemistry to the Clinic. *Met Ions Life Sci* **2019**, *19*, 331–357.

18. Sierra, M. A.; Casarrubios, L.; de la Torre, M. C., Bio-Organometallic Derivatives of Antibacterial Drugs. *Chem. Eur. J* **2019**, *25*, 7232-7242.

19. Ravera, M.; Moreno-Viguri, E.; Paucar, R.; Pérez-Silanes, S.; Gabano, E., Organometallic compounds in the discovery of new agents against kinetoplastid-caused diseases. *Eur. J. Med. Chem.* **2018**, *155*, 459-482.

20. Jürgens, S.; Casini, A., Mechanistic Insights into Gold Organometallic Compounds and their Biomedical Applications. *Chimia* **2017**, *71*, 92-101.

21. Lee, L. C.-C.; Leung, K.-K.; Lo, K. K.-W., Recent development of luminescent rhenium(i) tricarbonyl polypyridine complexes as cellular imaging reagents, anticancer drugs, and antibacterial agents. *Dalton Trans.* **2017**, *46*, 16357–16380.

22. Patil, S. A.; Patil, S. A.; Patil, R.; Keri, R. S.; Budagumpi, S.; Balakrishna, G. R.; Tacke, M., Nheterocyclic carbene metal complexes as bio-organometallic antimicrobial and anticancer drugs. *Future Med Chem* **2015**, *7*, 1305-33.

23. Patra, M.; Gasser, G.; Metzler-Nolte, N., Small organometallic compounds as antibacterial agents. *Dalton Trans.* **2012**, *41* (21), 6350-8.

24. Patra, M.; Wenzel, M.; Prochnow, P.; Pierroz, V.; Gasser, G.; Bandow, J. E.; Metzler-Nolte, N., An organometallic structure-activity relationship study reveals the essential role of a Re(CO)(3) moiety in the activity against gram-positive pathogens including MRSA. *Chem Sci* **2015**, *6*, 214-224.

25. Smitten, K. L.; Fairbanks, S. D.; Robertson, C. C.; Bernardino de la Serna, J.; Foster, S. J.; Thomas, J. A., Ruthenium based antimicrobial theranostics – using nanoscopy to identify therapeutic targets and resistance mechanisms in Staphylococcus aureus. *Chem. Sci.* **2020**, *11*, 70-79.

26. Smitten, K. L.; Thick, E. J.; Southam, H. M.; Bernardino de la Serna, J.; Foster, S. J.; Thomas, J. A., Mononuclear ruthenium(ii) theranostic complexes that function as broad-spectrum antimicrobials in therapeutically resistant pathogens through interaction with DNA. *Chem. Sci.* **2020**, *11*, 8828-8838.

27. Sierra, M. A.; Casarrubios, L.; de la Torre, M. C., Bio-Organometallic Derivatives of Antibacterial Drugs. *Chem. Eur. J.* **2019**, *25* (30), 7232-7242.

28. Frei, A., Metal Complexes, an Untapped Source of Antibiotic Potential? *Antibiotics* 2020, 9
(2).

29. Nasiri Sovari, S.; Zobi, F., Recent Studies on the Antimicrobial Activity of Transition Metal Complexes of Groups 6–12. *Chemistry* **2020**, *2* (2).

30. Frei, A.; Zuegg, J.; Elliott, A. G.; Baker, M.; Braese, S.; Brown, C.; Chen, F.; G. Dowson, C.; Dujardin, G.; Jung, N.; King, A. P.; Mansour, A. M.; Massi, M.; Moat, J.; Mohamed, H. A.; Renfrew, A. K.; Rutledge, P. J.; Sadler, P. J.; Todd, M. H.; Willans, C. E.; Wilson, J. J.; Cooper, M. A.;

Blaskovich, M. A. T., Metal complexes as a promising source for new antibiotics. *Chem. Sci.* **2020**, *11* (10), 2627-2639.

31. Frei, A.; Ramu, S.; Lowe, G. J.; Dinh, H.; Semenec, L.; Elliott, A. G.; Zuegg, J.; Deckers, A.; Jung, N.; Bräse, S.; Cain, A. K.; Blaskovich, M. A. T., Platinum Cyclooctadiene Complexes with Activity against Gram-positive Bacteria. *ChemMedChem* **2021**, *16* (20), 3165-3171.

32. Sovari, S. N.; Radakovic, N.; Roch, P.; Crochet, A.; Pavic, A.; Zobi, F., Combatting AMR: A molecular approach to the discovery of potent and non-toxic rhenium complexes active against C. albicans-MRSA co-infection. *Eur. J. Med. Chem.* **2021**, *226*, 113858.

33. Sovari, S. N.; Vojnovic, S.; Bogojevic, S. S.; Crochet, A.; Pavic, A.; Nikodinovic-Runic, J.; Zobi, F., Design, synthesis and in vivo evaluation of 3-arylcoumarin derivatives of rhenium(I) tricarbonyl complexes as potent antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA). *Eur. J. Med. Chem.* **2020**, *205*, 112533.

34. Coverdale, J. P. C.; Guy, C. S.; Bridgewater, H. E.; Needham, R. J.; Fullam, E.; Sadler, P. J., Osmium–arene complexes with high potency towards Mycobacterium tuberculosis. *Metallomics* **2021**, *13*.

35. Soldevila-Barreda, J. J.; Fawibe, K. B.; Azmanova, M.; Rafols, L.; Pitto-Barry, A.; Eke, U. B.; Barry, N. P. E., Synthesis, Characterisation and In Vitro Anticancer Activity of Catalytically Active Indole-Based Half-Sandwich Complexes. *Molecules* **2020**, *25*, 4540.

36. Wan, Y.; Li, Y.; Yan, C.; Yan, M.; Tang, Z., Indole: A privileged scaffold for the design of anticancer agents. *Eur. J. Med. Chem.* **2019**, *183*, 111691.

37. Dadashpour, S.; Emami, S., Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms. *Eur. J. Med. Chem.* **2018**, *150*, 9-29.

38. Lal, S.; Snape, T. J., 2-Arylindoles: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activity. *Curr. Med. Chem.* **2012**, *19*, 4828-4837.

39. Xu, H.; Lv, M., Developments of indoles as anti-HIV-1 inhibitors. *Curr. Pharm. Des.* **2009**, *15*, 2120-48.

40. Bacac, M.; Hotze, A. C. G.; Schilden, K. v. d.; Haasnoot, J. G.; Pacor, S.; Alessio, E.; Sava, G.; Reedijk, J., The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. *J. Inorg. Biochem.* **2004**, *98* (2), 402-412.

41. Peacock, A. F. A.; Melchart, M.; Deeth, R. J.; Habtemariam, A.; Parsons, S.; Sadler, P. J., Osmium(II) and Ruthenium(II) Arene Maltolato Complexes: Rapid Hydrolysis and Nucleobase Binding. *Chem. - Eur. J.* **2007**, *13* (9), 2601-2613.

42. Peacock, A. F. A.; Habtemariam, A.; Moggach, S. A.; Prescimone, A.; Parsons, S.; Sadler, P. J., Chloro Half-Sandwich Osmium(II) Complexes: Influence of Chelated N,N-Ligands on Hydrolysis, Guanine Binding, and Cytotoxicity. *Inorg. Chem.* **2007**, *46* (10), 4049-4059.

43. Scolaro, C.; Hartinger Christian, G.; Allardyce, C. S.; Keppler Bernhard , K.; Dyson Paul , J., Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(g6-p-cymene)Cl2(pta)]. *J. Inorg. Biochem.* **2008**, *102*, 1743-1748.

44. Liu, Z.; Sadler, P. J., Organoiridium Complexes: Anticancer Agents and Catalysts. *Accounts of Chemical Research* **2014**, *47* (4), 1174-1185.

45. Soldevila-Barreda, J. J.; Metzler-Nolte, N., Intracellular Catalysis with Selected Metal Complexes and Metallic Nanoparticles: Advances toward the Development of Catalytic Metallodrugs. *Chem. Rev.* **2019**, *119* (2), 829-869.

46. Meier-Menches, S. M.; Gerner, C.; Berger, W.; Hartinger, C. G.; Keppler, B. K., Structure– activity relationships for ruthenium and osmium anticancer agents – towards clinical development. *Chem. Soc. Rev.* **2018**, *47* (3), 909-928.

47. Rilak Simović, A.; Masnikosa, R.; Bratsos, I.; Alessio, E., Chemistry and reactivity of ruthenium(II) complexes: DNA/protein binding mode and anticancer activity are related to the complex structure. *Coord. Chem. Rev* **2019**, *398*, 113011.

48. Peacock, A. F. A.; Habtemariam, A.; Fernández, R.; Walland, V.; Fabbiani, F. P. A.; Parsons, S.; Aird, R. E.; Jodrell, D. I.; Sadler, P. J., Tuning the Reactivity of Osmium(II) and Ruthenium(II) Arene Complexes under Physiological Conditions. *J. Am. Chem. Soc.* **2006**, *128* (5), 1739-1748.

49. Cross, J. M.; Gallagher, N.; Gill, J. H.; Jain, M.; McNeillis, A. W.; Rockley, K. L.; Tscherny, F. H.; Wirszycz, N. J.; Yufit, D. S.; Walton, J. W., Pyridylphosphinate metal complexes: synthesis, structural characterisation and biological activity. *Dalton Trans.* **2016**, *45* (32), 12807-12813.

50. Mistry, S. N.; Shonberg, J.; Draper-Joyce, C. J.; Klein Herenbrink, C.; Michino, M.; Shi, L.; Christopoulos, A.; Capuano, B.; Scammells, P. J.; Lane, J. R., Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand. *J. Med. Chem.* **2015**, *58* (17), 6819-6843.

51. Kuuloja, N.; Tois, J.; Franzén, R., Indole-olefin-oxazoline (IndOlefOx)-ligands: synthesis and utilization in asymmetric Rh-catalyzed conjugate addition. *Tetrahedron: Asymmetry* **2011**, *22* (4), 468-475.

52. Guo, L.; Chatupheeraphat, A.; Rueping, M., Decarbonylative Silylation of Esters by Combined Nickel and Copper Catalysis for the Synthesis of Arylsilanes and Heteroarylsilanes. *Angew. Chem. Int. Ed.* **2016**, *55* (39), 11810-11813.

John al President